

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Nobuaki TAKAHASI *et al.*
Title: **ANTI-CD40 ANTIBODY MUTANTS**
Appl. No.: 10/584,345
Int'l Filing Date: 12/24/2004
371(c) Date: 02/26/2007
Examiner: Phillip GAMBEL
Art Unit: 1644
Confirmation No.: 3671

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants submit the accompanying Form PTO/SB/08, a listing of documents known to them, in order to comply with 37 CFR §1.56. A copy of each non-U.S. patent document and each non-patent document also is submitted, per 37 CFR §1.97 and §1.98.

The present submission of any document, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of this application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants waive no right to take any action that would be appropriate to antedate or otherwise to remove as a competent reference any document determined to be a *prima facie* art reference against claims of the application.

TIMING OF THE DISCLOSURE

The listed documents are submitted in compliance with 37 CFR §1.97(b), before the mailing of a first Office action after the filing of a Request for Continued Examination under §1.114.

RELEVANCE OF EACH DOCUMENT

Documents listed on the attached PTO/SB/08 was cited during the prosecution of the corresponding European and Korean applications. A copy of the European and Korean Office Actions is provided, setting forth the portion of each document deemed relevant by the overseas examiner. An English-language counterpart of the Korean Office Action document is not available. The absence of a translation does not relieve the PTO from its duty to consider any submitted document (37 CFR §1.98 and MPEP§609).

Applicants request that the examiner consider and make of record each listed document, and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

STATEMENT

In accordance with 37 CFR §1.704(d), the undersigned hereby states that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR §1.56(c) more than thirty days prior to the filing of the information disclosure statement.

Although applicants believe that no fee is required, the Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 19-0741.

Respectfully submitted,

Date October 15, 2011

By /Stephen A. Bent/

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5404
Facsimile: (202) 672-5399

Stephen A. Bent
Attorney for Applicant
Registration No. 29,768